Molecular Pathology and Genomics Core

项目摘要 核心C提供专业的专业和技术病理学服务和基因组服务 这对该计划的成功至关重要。它通过实现3个总体目标来实现这一目标， 三个P01项目：1）提供原发性人类PTCL和PDX分类所需的病理学专业知识 和鼠PTCL模型; 2）对与理解PTCL相关的生物标志物进行标准和新的原位测试， PTCL病理生理学及其对新疗法的反应和抗性;以及3）进行靶向外显子组 对大量充分表征的人PTCL进行测序。核心提供这些服务， 一个位于波士顿，由乔恩·阿斯特领导，将提供支持目标1和2的服务， 第二个在北卡罗来纳州，由Sandeep Dave领导，将提供支持目标1和3的服务。递送 Aim 1服务的核心依赖于核心的共同领导人Jon Aster博士，他是一位实践学者 具有>25年人类和鼠血液病理学经验的血液病理学家， 补充项目1（John Chan）的额外专业知识，并获得血液肿瘤 研究联盟，其中包括>25个机构，并已累计超过1800例T细胞淋巴瘤， 大多数是成对的正常组织目标2服务将在波士顿提供，包括标准组织学和 免疫组织学服务和创新的多参数免疫荧光染色平台，Perkin- Elmer Vectra平台和CyCIF是一种迭代成像平台，可用于评价>50种不同的 单个FFPE载玻片上的标记。Aim 3服务在北卡罗来纳州的演出现场由 对淋巴瘤中经常突变的410个基因进行靶向外显子组测序，最初使用 从1833例PTCL和配对正常组织对照的队列中制备DNA。

PROJECT SUMMARY Core C provides access to specialized professional and technical pathology services and genomic services that are essential to the success of the Program. It does so by carrying out 3 overarching aims that support all three P01 Projects: 1) provide pathology expertise needed for classification of primary human PTCLs and PDX and murine PTCL models; 2) perform standard and novel in situ tests for biomarkers relevant to understanding PTCL pathophysiology and its response and resistance to novel therapies; and 3) perform targeted exome sequencing of a large cohort of well-characterized human PTCLs. The Core delivers these services at two performance sites, one in Boston led by Jon Aster, which will deliver services supporting Aims 1 and 2, and the second in North Carolina led by Sandeep Dave, which will deliver services supporting Aims 1 and 3. Delivery of Aim 1 services relies on the Core's co-leader, Dr. Jon Aster, who is a practicing academic hematopathologist with >25 years of experience with human and murine hematopathology, and is supplemented by additional expertise in Project 1 (John Chan) and access to the Hematologic Malignancies Research Consortium, which includes >25 institutions and has accrued over 1800 cases of T cell lymphomas, a majority with paired normal tissue. Aim 2 services will be provided in Boston include standard histology and immunohistology services and innovative, multiparametric immunofluorescence staining platforms, the Perkin- Elmer Vectra platform and CyCIF is an iterative imaging platform that allows for evaluation of >50 different markers on single FFPE slides. Aim 3 services are delivered at the North Carolina performance site by performing targeted exome sequencing on 410 genes that are frequently mutated in lymphoma, initially using DNA prepared from a cohort of 1833 PTCLs and paired normal tissue controls.